It is, thus, not surprising that V1b receptor antagonists, inhibiting AVP and CRH-induced ACTH release, have raised experimental interest as potential agents for the treatment of stress-related disorders and MDD (95). The gene discussed is AVPR1B; the disease is stress-related disorder.